These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 26992209

  • 1. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
    Lee B, Lee T, Lee SH, Choi YL, Han J.
    Oncotarget; 2016 Apr 26; 7(17):23874-84. PubMed ID: 26992209
    [Abstract] [Full Text] [Related]

  • 2. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M.
    J Thorac Oncol; 2017 Apr 26; 12(4):681-688. PubMed ID: 28007627
    [Abstract] [Full Text] [Related]

  • 3. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J, Kobayashi Y, Urayama KY, Yamaura H, Yatabe Y, Hida T.
    PLoS One; 2016 Apr 26; 11(8):e0161081. PubMed ID: 27518729
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N, Frattini M, Bernasconi B, Zappa F, Schiavone G, Wannesson L, Antonelli P, Balzarini P, Sessa F, Mazzucchelli L, Tibiletti MG, Martin V.
    Clin Lung Cancer; 2016 Jan 26; 17(1):56-61. PubMed ID: 26381283
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W, Zhang Z, Guo L, Qiu T, Ling Y, Cao J, Guo H, Zhao H, Li L, Ying J.
    Oncotarget; 2016 Feb 16; 7(7):8332-40. PubMed ID: 26789109
    [Abstract] [Full Text] [Related]

  • 12. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L, Zhang L, Wang C, Zhang H, Wei L.
    Tumour Biol; 2015 Aug 16; 36(8):6417-24. PubMed ID: 25813151
    [Abstract] [Full Text] [Related]

  • 13. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A.
    Clin Lung Cancer; 2016 Sep 16; 17(5):384-390. PubMed ID: 26712101
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF, Chen XY, Yu XB.
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr 08; 45(4):221-5. PubMed ID: 27033383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.